Griseofulvin compound and pharmaceutical use thereof
US-11993593-B2 · May 28, 2024 · US
Method of treatment
US10179119B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10179119-B2 |
| Application number | US-201515326934-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 29, 2015 |
| Priority date | Sep 2, 2014 |
| Publication date | Jan 15, 2019 |
| Grant date | Jan 15, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
First claim
Opening claim text (preview).
What is claimed is: 1. A method for the treatment of sleep disturbances in a patient with Smith-Magenis Syndrome that comprises internally administering to the patient an effective amount of tasimelteon once daily before bedtime. 2. The method of claim 1 , wherein the treatment of sleep disturbance is manifested as an improvement in nighttime sleep. 3. The method of claim 2 , wherein the improvement in nighttime sleep is manifested as a reduction in the percentage of wake period within the patient's sleep interval. 4. The method of claim 1 , wherein the treatment of sleep disturbances is manifested as improvement in one or more of the following: total amount of nighttime sleep; number, timing, and length of nighttime awakenings; sleep onset; wake time; number, timing, and length of daytime naps; improvement in clinical global impression of change (CGI-C); improvement in clinical global impression of severity (CGI-S); and improvement in behavior. 5. The method of claim 1 , wherein the dose of tasimelteon is between about 5 mg/day and about 100 mg/day. 6. The method of claim 5 , wherein the dose of tasimelteon is about 20 mg/d. 7. The method of claim 1 , wherein the tasimelteon is administered between one-half hour and two hours before bed time. 8. The method of claim 7 , wherein the tasimelteon is administered between one-half hour and one and one-half hours before bed time. 9. The method of claim 8 , wherein the tasimelteon is administered one hour before bed time. 10. The method of claim 1 , wherein the treatment effects are maintained by ongoing daily administration of tasimelteon.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Hypnotics; Sedatives · CPC title
- A61K31/343Primary
condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone · CPC title
Medicinal preparations containing organic active ingredients · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10179119B2 cover?
- Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
- Who is the assignee on this patent?
- Vanda Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/343. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).